ReviewEJNMMI radiopharmacy and chemistry2023
Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?
Review in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Challenging the Macrocycle Paradigm: Four-Arm, High-Denticity Acyclic Chelators for Radiopharmaceuticals Incorporating Actinium and Lanthanides.Inorganic chemistry · 2026Article
- RadioPharm: the database of radiopharmaceuticals.Nucleic acids research · 2026Article
- Challenges in radiopharmaceutical importation across six Southern African Development Community countries: an exploratory study.Frontiers in medicine · 2026Article
- Quantitative SPECT/CT: Technique and Clinical Applications.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Age- and sex-specific cancer risk predictions for some important radionuclides in a Swedish population-use of the updated ORNL computation method for chronic exposure.Radiation protection dosimetry · 2025Article
- Novel radionuclides: demand, production and distribution for translational research in Europe.EJNMMI radiopharmacy and chemistry · 2024Review
- PYTA: a universal chelator for advancing the theranostic palette of nuclear medicine.Chemical science · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 5 countries.
Funding
Abstract
backgroundIn order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe. MAIN BODY: A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. A total of 40 preclinical/clinical users institutions took part in the survey. Clinical end users currently use the following radionuclides in their studies:
conclusionsThanks to a questionnaire distributed by the PRISMAP consortium, the current status and needs of clinical end-users in nuclear medicine were identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.